Hadiza Shu'Aib Kazaure, MD
Surgical Oncology · Durham
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 4
- Since medical school
- 14 years
- Yale University School of Medicine, 2012
Offices
4 locations · Duke Health Integrated Practice Inc · 3,140 clinicians in this group
Hospitals listed: Duke University Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Kazaure’s office at (919) 684-8111 to ask if they take your plan before you enroll.
California Medical Board record
Licence A126415 · Delinquent
Licence status: Delinquent · since 2013 · expires 2025-02-28 · Yale University School of Medicine.
License renewal fee has not been paid. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Surgery - Surgery
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Duke University HospitalDurham, NCAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of Duke University Health System, which runs 3 hospitalsHome of Duke Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Death rate among surgical inpatients with serious treatable complications: 216.01 (186.77 to 245.25) · 366 cases, Jul 2022 – Jun 2024Worse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.5 (4.26 to 6.75) · 6,581 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative acute kidney injury requiring dialysis rate: 2.95 (2.11 to 3.79) · 3,680 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.374, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.727, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.398, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.592, Oct 2024 – Sep 2025Better than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 8.6 (7.5 to 9.8) · 2,101 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Duke University Hospital
Behind the star rating — Deaths: 4 better, 3 the same, 1 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 8 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 216.01 (186.77 to 245.25) · 366 cases | Worse | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.5 (4.26 to 6.75) · 6,581 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.95 (2.11 to 3.79) · 3,680 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.374 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.727 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.398 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.592 | Better | Oct 2024 – Sep 2025 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 8.6 (7.5 to 9.8) · 2,101 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.91 (0.21 to 1.61) · 4,083 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.1 (0.94 to 1.26) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.6 · 277 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 175 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.4 · 351 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.1 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 9.6 · 530 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.4 · 684 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.3 · 10,510 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.32) · 15,279 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.04 to 0.36) · 16,992 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.62 (1.69 to 3.56) · 5,880 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.88 (6.29 to 11.47) · 3,482 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (4.07 to 7.84) · 3,644 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.49 (1.26 to 3.72) · 1,495 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.5 (0.15 to 0.85) · 14,819 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.9 · 293 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 1.373 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.048 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.7 · 688 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 1,551 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 7.3 · 428 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -20.2 · 963 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -14.2 · 554 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.9 · 861 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.9 (4.1 to 5.8) · 2,101 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.9 · 320 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.7 · 312 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.1 · 367 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.2 to 16) · 2,489 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1) · 2,623 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,341 patients answered, 22% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 82% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 90% |
| Yes, staff "did" give patients information about help after discharge | 90% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 82% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 78% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 58% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 49% |
| Yes, staff "did" give patients information about possible symptoms | 91% |
Original Medicare doctor bills
$21,878
Medicare paid this office $21,878 for 50 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| New patient visit (60+ min) | 18 | $2,116 | $118 |
| Ultrasound scan of head and neck soft tissue | 12 | $238 | $20 |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Removal or exploration of parathyroid glands | – | – | – | – | 13 | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
50 Original Medicare patients in 2024. Average age 72 · Women 64% · Health risk score 1.48. At or below the middle of the specialty; the typical surgical oncology clinician is at 1.48.
Conditions among them: High blood pressure 75% · Diabetes 42% · Chronic kidney disease 40% · Depression 32% · Cancer 30% · Coronary heart disease 28% · Atrial fibrillation 26%.
The office billed $106,529, Medicare allowed $27,851 and paid $21,878; for 93 services of 21 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 50 | 93 | 72 | 1.48 | $106,529 | $21,878 |
| 2023 | 58 | 106 | 71 | 1.61 | $142,801 | $26,562 |
| 2022 | 49 | 94 | 70 | 1.29 | $94,891 | $20,189 |
| 2021 | 33 | 54 | 70 | 1.18 | $64,930 | $13,014 |
| 2020 | 28 | 47 | 69 | 1.39 | $54,735 | $10,917 |
| 2019 | 22 | 45 | 68 | 1.42 | $65,774 | $12,773 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Removal or exploration of parathyroid glands | 13 | $9,114 | $701 |
| New patient visit (60+ min) | 22 | $2,965 | $135 |
| New patient visit (45+ min) | 11 | $1,025 | $93 |
| Ultrasound scan of head and neck soft tissue | 16 | $325 | $20 |
2022: 2 services
| New patient visit (60+ min) | 26 | $3,304 | $127 |
| Ultrasound scan of head and neck soft tissue | 24 | $504 | $21 |
2021: 1 service
| New patient visit (45+ min) | 19 | $1,919 | $101 |
2020: 1 service
| New patient visit (45+ min) | 22 | $2,128 | $97 |
2019: 1 service
| New patient visit (60+ min) | 11 | $1,423 | $129 |
Drugs they prescribed that Part D paid
$61
Pharmacies billed $61 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
14 generic and 0 brand-name prescriptions · $61 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
Year by year
| 2024 | 14 | None | None | 0% | $61 |
| 2023 | 15 | None | None | 0% | $168 |
| 2022 | 11 | None | None | None | $77 |
| 2021 | 18 | None | None | None | $1,971 |
| 2018 | 54 | 25 | 33% (18) | 22% | $565 |
| 2017 | 66 | 43 | 52% (34) | 23% | $913 |
| 2016 | 52 | 44 | 83% (43) | None | $909 |
| 2015 | 35 | 30 | 74% (26) | None | $1,738 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2018: 1 drug
| Levothyroxine | 15 | $174 | $12 |
2017: 2 drugs
| Levothyroxine | 19 | $313 | $16 |
| Hydrocodone-Acetaminophen | 16 | $195 | $12 |
2016: 1 drug
| Hydrocodone-Acetaminophen | 30 | $548 | $18 |
2015: 1 drug
| Hydrocodone-Acetaminophen | 18 | $384 | $21 |
Money from drug and device companies
$16 in 2025
A payment is not proof that care is biased.
| E.R. Squibb & Sons L.L.C. | Camzyos | $16 | 1 payment
|
See the published payment
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-28 | Camzyos | $16 |
Professional record
- NPI
- 1548526312
- Licence
- CA A126415California A126415: Delinquent · expires 2025-02-28
- Trained
- Yale University School of Medicine, 2012 · 14 years ago
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Surgery (208600000X)
- Mailing address
- 466g Seeley Mudd Office 484, Durham, NC, 27710
- NPI first listed
- 2012-04-05
- NPI last updated
- 2021-03-19
- NPI record certified
- 2021-03-19
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, Palo Alto, CA, 94304